Indigenous Covid-19 vaccine Covaxin has demonstrated
interim clinical efficacy of 81 per cent in its phase three trial. The
trial involved 25 thousand 800 participants across 21 sites.
The first interim analysis is based on 43 cases of which 36 cases of
Covid-19 were observed in the placebo group versus 7 cases observed in
the Covaxin group resulting in vaccine efficacy of 81 per cent.
The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research.
Director-General of Indian Council of Medical Research, Dr. Balram
Bhargava said that the journey of completely indigenous COVID-19 vaccine
in less than eight months’ time showcases the immense strength of
Atmanirbhar Bharat. He said, it is also a testament to India’s emergence
as a global vaccine superpower.
Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said
that Covaxin demonstrated high clinical efficacy against Covid-19 and
significant immunogenicity against the rapidly emerging variants.
Social media is bold.
Social media is young.
Social media raises questions.
Social media is not satisfied with an answer.
Social media looks at the big picture.
Social media is interested in every detail.
social media is curious.
Social media is free.
Social media is irreplaceable.
But never irrelevant.
Social media is you.
(With input from news agency language)
If you like this story, share it with a friend!
We are a non-profit organization. Help us financially to keep our journalism free from government and corporate pressure
0 Comments